From DCAT Value Chain Insights (VCI)
Rentschler Biotechnologie, a contract manufacturing organization for the development and production of biopharmaceuticals, has appointed Dr. Frank Mathias as chief executive officer (CEO) effective 1 April 2016. Dr. Mathias had previously been a member of the supervisory board at Rentschler. Former CEO, Dr. Nikolaus F. Rentschler, is moving to the supervisory board to concentrate on the further expansion of the Rentschler group.
Dr. Mathias studied pharmacy at the Paris VI university where he graduated in 1991. He has gained more than 25 years’ experience in leading positions in the pharmaceutical and biotech industry. His industrial career began when he assumed a position as international product manager at Hoechst AG. After that, he became CEO of Servier Deutschland and Amgen Deutschland. In 2009 he became CEO at Medigene AG, where he had formerly taken responsibility for marketing, sales and business development.
Source: Rentschler Biotechnologie
Thank you for reading DCAT Value Chain Insights (VCI), an information resource from the
Drug, Chemical & Associated Technologies Association (DCAT).
Learn more and sign up to receive a complimentary subscription